Increased plasminogen activator inhibitor activity and diabetes predict subsequent coronary events in patients with angina pectoris

Annals of Medicine

Volumn 33, Issue 3, 2001, Pages 206-212

  Takazoe, K ^a   Ogawa, H ^a   Yasue, H ^a   Sakamoto, T ^a   Soejima, H ^a   Miyao, Y ^a   Kawano, H ^a   Moriyama, Y ^a   Misumi, K ^a   Suefuji, H ^a   Kugiyama, K ^a   Yoshimura, M ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Coronary events; Diabetes; Plasminogen activator inhibitor

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE MARKER; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SUDDEN DEATH;

EID: 0035003849     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853890109002079     Document Type: Article

References (32)

1. Lewis A Conner memorial lecture. Mechanism leading to myocardial infarction: Insights from studies of vascular biology
2. Specific platelet mediators and unstable coronary artery lesions
3. Kinetics of the activation of plasminogen by natural and recombinant tissue-type plasminogen activator
4. Evidence for the occurrence of a fast-acting inhibitor of tissue-type plasminogen activator in human plasma
5. Initiation and regulation of fibrinolysis in human plasma at the plasminogen activator level
6. Type 1 plasminogen activator inhibitor
7. Plasminogen activator inhibitor in plasma: Risk factor for reccurent myocardial infarction
8. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
9. Morbidity and mortality in diabetics in the Framingham population: Sixteen year follow-up study
10. Diabetes and obesity
11. Clustering of heart disease risk factors in diabetic compared to nondiabetic adults
12. Risk factors for mortality from all causes and from coronary heart disease among persons with diabetes
13. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus
14. Hypofibrinolysis associated with vasculopathy in non-insullin dependent diabetes mellitus
15. Fibrinolytic disorders in diabetes mellitus
16. Involvement of the hemostatic system in the insulin resistance syndrome: A study of 1500 patients with angina pectoris
17. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects
18. Diurnal variation of tissue plasminogen activator and its rapid inhibitor (PAI-1)
19. Plasma plasminogen activator inhibitor activity and tissue plasminogen activator levels in patients with unstable angina and those with coronary spastic angina
20. Association of patency of the infarct-related coronary artery with plasma levels of plasminogen activator inhibitor activity in acute myocardial infarction
21. Determination of plasminogen activator inhibitor in plasma using t-PA and a chromogenic single-point poly-D-lysine stimulated assay
22. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
23. Inceased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study
24. Comparative analysis of plasminogen activator inhibitor-1 expression in different types of atherosclerotic lesions in coronary arteries from human heart explants
25. Association of fibrinolytic parameters with early atherosclerosis: The ARIC Study
26. Coagulation activation in patients undergoing directional coronary atherectomy
27. Impaired fibrinolysis early after percutaneous transluminal angioplasty is associated with restenosis
28. Diabetes and atherosclerosis: An epidemiologic view
29. Family history of diabetes and cardiovasucular disease risk factors and mortality among euglycemic, borderline hyperglycemic, and diabetic adults
30. Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy, and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients
31. NIDDM and its metabolic control predict coronary heart disease in elderly subjects
32. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects